Key figures
Nightingale Health's key figures
| EUR thousand | Group 2023–2024 | Group 2022–2023 |
Revenue | 4,358 | 4,182 |
EBITDA | -10,434 | -11,835 |
Operating profit (loss) | -18,592 | -18,524 |
Net income (loss) for the financial period | -17,463 | -18,083 |
Equity ratio | 92% | 92% |
Net debt to equity ratio | -76% | -78% |
Balance sheet total | 90,840 | 106,793 |
Number of employees on average | 84 | 82 |
Employee benefits* | -8,783 | -9,381 |
Net cash at the end of the period | 63,401 | 75 615 |
| Earnings per share (EPS), undiluted and diluted**, EUR | -0.29 | -0.30 |
* Employee benefits include expenses in accordance with the IFRS 2 Share based payments standard, which totaled EUR 2.93 (3.95) million in the financial year.
** The company’s potential dilutive instruments consist of stock options. As the company’s business has been unprofitable, stock options would have an anti-dilutive effect and therefore they are not taken into account in calculating the dilutive loss per share. Thus, there is no difference between the undiluted and diluted earnings per share.
Calculation of key figures
Key figure | Formula |
EBITDA | Operating profit (loss) before depreciation and amortization |
Operating profit (loss) | Profit (loss) before income taxes and financial income and expenses |
Equity ratio, % | Total equity / (Balance sheet total – deferred income) |
Net debt to equity ratio, % | Net debt /Total equity |
Earnings per share (EPS), undiluted, EUR | Profit (loss) for the period / weighted average number of shares outstanding during the period |
Earnings per share (EPS), diluted, EUR | Profit (loss) for the period / weighted average number of shares outstanding during the period + potential dilutive shares |
| Relative share trading volume, % | Number of shares traded during the financial period / average number of shares |
| Net cash | Cash and cash equivalents + current investments – interest-bearing debt – lease liabilities |